Pharmaceutical giant Pfizer will likely know by the end of next month if its coronavirus vaccine is effective, CEO Albert Bourla said.
There’s a “more than 60 percent” chance that the drugmaker’s clinical research will produce results by the end of October showing whether or not the shot works, Bourla said in a Sunday TV interview.
Pfizer has already started producing the vaccine it’s developing with German biotech firm BioNTech even though there’s no guarantee that its Phase 3 study will be successful, according to Bourla, who said it’s a “likely scenario” that the US Food and Drug Administration will approve the shot by the end of 2020.
“We have already manufactured hundreds of thousands of doses, so just in case we have a good study readout, conclusive, and FDA plus the advisory committee feels comfortable, that we will be ready,” Bourla told CBS’s “Face the Nation,” apparently referring to the FDA’s vaccine panel.
Pfizer is working to diversify